Objectives: Findings from nonrandomized studies on safety or efficacy of treatment in patient subgroups may trigger postlaunch randomized clinical trials (RCTs). In the analysis of such RCTs, results from nonrandomized studies are typically ignored. This study explores the trade-off between bias and power of Bayesian RCT analysis incorporating information from nonrandomized studies.
Bayesian methods including nonrandomized study data increased the efficiency of postlaunch RCTs 
Introduction
Randomized clinical trials (RCTs) are the gold standard to assess effects of interventions (eg, a drug or surgical procedure). An important reason for this is that random allocation of treatment prevents confounding. It is well known, however, that RCTs are usually underpowered to detect adverse events or treatment effect modification (ie, underpowered to detect differences in treatment effects between patient subgroups) [1, 2] . It is therefore possible that signals of effect modification or adverse events are only detected after marketing of the treatment in postlaunch nonrandomized studies (eg, case-control or cohort studies). Such signals may then lead to the initiation of new (subgroup-specific) RCTs in an attempt to provide more evidence on which patient group(s) benefit (most) from treatment.
An example of treatment effect modification is the effect of the oral antidiabetic drug rosiglitazone, a type of thiazolidinedione (TZD), on bone fractures: rosiglitazone increases the risk of bone fractures in women but not in men [3e5] . Customarily, postlaunch RCTs are analyzed without incorporating information from nonrandomized studies. On the other hand, including information from nonrandomized studies in the analysis of RCTs may decrease the required number of subjects for that trial. This may be particularly important in What is new?
Key findings
Postlaunch randomized clinical trials (RCTs) are usually initiated to answer questions on intended or unintended effects of therapy in subgroups. Often these effects are harder to detect than main effects of therapy and therefore require a larger sample of patients.
Depending on the quality of the nonrandomized study results, incorporating such evidence in the analysis of postlaunch RCTs can increase power and precision of results and thus decrease sample size.
What this adds to what was known?
Nonrandomized studies on therapy effects are vulnerable to bias. This has led some researchers to discount results for nonrandomized studies altogether; for example, most systematic reviews focus exclusively on evidence from RCTs. With the advent of health care databases, however, data quality of nonrandomized studies has increased, potentially decreasing bias. On the other hand, RCTs have begun using less stringent selection criteria, resulting in a patient sample better reflecting clinical practice. This article showed that including results from nonrandomized studies frequently increases bias. However, this increase in bias may be outweighed by an increase in power, precision, and decrease in sample size.
What is the implication and what should change now?
Knowledge on intended or unintended subgroupspecific effects of therapy is important to decide which patients will benefit from therapy. Because of sample size constraints, most RCTs are unlikely to detect these important effects. One possibility to resolve this is to incorporate results from nonrandomized studies in RCT analysis, using informative Bayesian priors. Clearly, posterior results depend heavily on the choice of prior and hence on the quality of the nonrandomized studies. When results from RCTs and nonrandomized studies agree, incorporating results from both study types results in a meaningful increase in power and precision. Obviously, when RCTs and nonrandomized studies disagree, this is not the case. However, in such scenarios, the benefit of a Bayesian analysis is that the need for further research, exploring this contradictory evidence, is made glaringly apparent.
studies of treatment effect modification or adverse advents because these typically require considerably more patients than studies exploring average treatment effects [1, 2] .
The validity of an RCT analysis that incorporates information from nonrandomized studies will heavily depend on the quality (ie, validity) of the latter. Unless the results from the nonrandomized studies are centered on the RCT estimate, an increase in bias is likely. However, with the advent of health care databases [6] developed specifically for research, such as CPRD (www.cprd.com) or PHARMO (www.pharmo.nl), the quality of nonrandomized studies may have increased. For example, these databases may decrease bias by allowing for better confounder control through improved data quality, more appropriate selection of comparators, and a decreased likelihood of loss to follow-up. Furthermore, if bias is constant across subgroups, this will cancel out when assessing the ratio of treatment effects in two patient subgroups, resulting in a correct estimate of interaction. For example, assume that the true risk ratio (RR) in men equals 1.00 and 2.00 in women; the interaction effect is 1.00/2.00 5 0.50. If both RRs were biased upward by 40%, for example, due to confounding, the interaction effect would still be (1.00 Â 1.40)/ (2.00 Â 1.40) 5 0.50. Unfortunately, the assumption of equal bias is untestable without knowing the ''true'' effect. However, even when this assumption is not exactly met, estimates of interaction effects will likely be less biased than main effect estimates. Given that most RCTs lack power to detect interaction effects and the increased potential to adjust for confounding in nonrandomized studies, it might be time to more seriously consider combining results from both sources.
One way of incorporating information from nonrandomized studies in the analysis of a RCT is by means of Bayesian statistics [7] . Although not the only way to incorporate results from previous studies, Bayesian methods are intuitively appealing because of their ease of reweighing prior knowledge, depending on for example its perceived relevance or validity [8] . Previously, informative Bayesian methods have been used to include prior knowledge in phase I and II trials [9, 10] . In phase III trials, Bayesian methods have been used to incorporate prior knowledge in the analysis of the control group [11] . In this manuscript, we elaborate on this by exploring the trade-off between bias and power of a phase IV RCT using prior knowledge from nonrandomized postmarketing studies. Performance of such an approach was evaluated using a simulation study, based on the aforementioned example of effect modification by gender of rosiglitazone on the risk of bone fracture.
Methods
In the following, we first describe the clinical example of rosiglitazone use and the risk of hip fracture, which was the starting point for the simulations. Second, we describe the frequentist and Bayesian analyses that were performed on the simulated data. Finally, we describe the different parameters that were varied across simulations. 
Statistical analyses
The typical frequentist analysis, a test ignoring prior knowledge, used by most RCTs was considered as the reference. We assumed that the gender-specific treatment effects (the natural logarithm of the OR) were approximately normally distributed and Wald-based 95% CI were constructed. Let y i indicates the natural logarithm of the OR, ln(OR), of rosiglitazone in males (i 5 1) or females (i 5 2). Interaction effects were calculated by subtracting y 2 from y 1 , and the variance in the natural logarithm of the interaction effect was derived by taking the sum of the variances ½s 2 i in gender-specific ln(OR) [12, 13] . Bayesian methods were implemented by combining the previously mentioned gender-specific likelihoods with conjugate (normally distributed) gender-specific priors: Nðx i ; t 2 i Þ with the hyperparameter x i representing the gender-specific mean ln(OR) of treatment and t 2 i the corresponding variance in x i . Given that the variance ðt 2 i Þ of an OR depends on its mean, we assumed this variance to be known.
The following four prior distributions were applied. First, as a reference, a noninformative prior was used, with hyperparameters x i 50 and t 2 i 510 6 . Second, three informative prior distributions were used with different precisions (ie, different variance hyperparameters) denoted skeptical, equivalent, and optimistic (Fig. 1) . For the skeptical prior, t By setting the variance hyperparameter proportional to variance in the RCT treatment effect estimates, the skeptical and equivalent priors prevent the prior information from over influencing the data [14] . The hyperparameter of the optimistic prior was set to t 2 i 50:027, which was similar to the precision of the main effect of original RCT meta-analysis [5] .
The hyperparameters of x i were based on the reported nonrandomized treatment effect estimates presented in Table 1 . To further incorporate the uncertainty around the true treatment effect, the hyperparameter, x i , was set to the point estimates [ln(1.05) in men; ln(1.44) in women], the lower bound of the 95% CI [ln(0.96); ln(1.35)] or the upper bound [ln(1.14); ln(1.53)] of the gender-specific treatment effects observed in the empirical IPDMA (Table 1) .
Finally, using the previously defined gender-specific likelihoods and priors, the posterior mean b u i and variance b d 2 i were estimated using Equation (1) .
95% credibility intervals (95% CrI) were created using the posterior mean and the 2.5th and 97.5th percentiles. Posterior standard deviations for the gender-specific ln(ORs) of treatment were estimated by taking the square root of b d 2 i ; after frequentist practice, these will subsequently be referred to as the standard error (SE). The posterior interaction effect was defined as b u 1 À b u 2 , and the variance in interaction effect was estimated by summing the variances ð b d 2 i Þ of the gender-specific treatment effect estimates (on the natural logarithmic scale) [12, 13] . Abbreviations: TZDs, thiazolidinediones; RCT, randomized clinical trial. a The empirical RCT data were used to simulate a new RCT and were combined with prior information based on the nonrandomized data. RCT data consisted of 11,401 subjects, of whom 346 experienced a bone fracture; the nonrandomized data consisted of 1,637,084 patients, of whom 32,244 experienced a bone fracture. Presented RCT effect estimates are unadjusted for covariables, whereas nonrandomized estimates are adjusted for potential confounders. Interaction effects are the ratio of the subgroup-specific effects and measure how much the treatment effect is modified by gender.
Simulations
A basic RCT scenario was created with gender-specific treatment effects (OR) of 1.00 in men and 2.23 in women resulting in an interaction OR of 0.45. Postlaunch RCTs with 1,000, 5,000, or 10,000 subjects were created. Subjects were equally divided between exposure groups and between genders. Dichotomous outcome data (bone fracture yes/no) per gender-specific subgroup were generated using random draws from a binomial distribution, with the outcome incidence in the comparator group set to 0.03 in women and 0.02 in men. All simulations were repeated 10,000 times, using the R statistical package for Windows version 3.0.2, Vienna, Austria [15] .
In the basic scenario (I), the type 1 error rate was explored among males (true OR 5 1.00) and power was evaluated among females (true OR 5 2.23) and for the interaction effect (ie, 0.45). To also evaluate type 1 error rates of the interaction effect, additional scenarios were created (Table 2) . In scenario II, the gender-specific ORs from the RCT were set to 2.23 in both subgroups, resulting in an interaction OR of 1.00. In scenario III, the genderspecific ORs from the RCT were set to 1.00 in both subgroups. In scenario IV, we explored the performance of the Bayesian of interaction tests when the prior information contradicted the simulated data (OR 1 5 1.00 and OR 2 5 2.23), by setting the prior hyperparameter x for Fig. 1 . Probability density distributions of simulated randomized clinical trial (RCT) data (N 5 5,000) and three informative priors. The mean odds ratio (OR) of the simulated RCT data was 1.00, 2.23, and 0.45 for the rosiglitazone effect in men, women, and their interaction. For the informative priors, the mean OR was set to 1.05, 1.44, and 0.73, based on results from nonrandomized studies (see Table 1 ).
men to ln(1.35), ln(1.44), or ln(1.53) and the prior ln(OR) for women to ln(0.96), ln(1.05), or ln(1.14). Finally, all scenarios were repeated with a different gender distribution in the simulated RCT population: 15% women (results presented in Appendix Tables 1e4 at www.jclinepi.com).
Performance of the frequentist and Bayesian analyses was evaluated using mean OR, mean SE, power, type I error rate, and mean bias. Power was defined as the proportion of times the 95% CrI or 95% CI excluded an OR of 1, when there was an effect. The type 1 error rate was defined as the proportion of times the 95% CrI or 95% CI excluded an OR of 1, when in fact there was no treatment effect. Mean bias was defined as the mean difference between the true treatment effect (Table 1 , RCT column) and the estimated treatment effect on the natural logarithmic scale.
Results
In the basic scenario (Table 3) , subgroup-specific rosiglitazone effect estimates in men were around 1.00, independent of simulated RCT size and the type of analyses. Type 1 error rates for the frequentist and noninformative priors were at most 5% and lower for the informative priors (range 0%, 3%). Subgroup-specific treatment effect estimates in women differed between the analytic methods applied and depended on the prior. For example, for a sample size of 1,000, ORs for noninformative, skeptical, equivalent, and optimistic priors was 2.33, 2.13, 1.83, and 1.51, respectively. Stated otherwise, bias (Table 3) increased by adding prior knowledge and was largest with the optimistic Bayesian analysis (bias range À0.04, 0.12). Despite bias towards a neutral effect of 1, power improved by adding prior knowledge. For example, in an RCT of 1,000 subjects, the power to detect a treatment effect in the subgroup of females was 40% for the frequentist analysis and between 87% and 100% for Bayesian analysis with an optimistic prior ( Table 3 ). This increase in power was driven by a decrease in SE that offset the increase in bias. This also translated in an increased power for the interaction test: 62% power for the frequentist analysis compared with 83%d93% using an optimistic prior.
To explore the type 1 error rates of the interaction effect, we simulated an RCTwhere the true OR in men and in women was 2.23 (ie, no interaction). Type 1 error rates of the frequentist, noninformative prior, and skeptical prior interaction tests were 5% (Table 4) . Using an equivalent prior, the type 1 error rate could be as high as 10% (N 5 10,000), but generally, the rate was below 5% (N 5 5,000 or 1,000). Type 1 error rates as high as 20% were found for Bayesian analyses using optimistic priors. Finally, in scenarios in which the main effect was absent (ie, OR in men and women was 1.00, Appendix Table 5 at www.jclinepi.com), the type 1 error rates of the interaction tests were generally lower, with a maximum of 8% for the optimistic prior.
To assess the impact of incorrectly specifying the prior mean hyperparameter, analyses were performed in which the priors contradicted the RCT, for example, a prior interaction effect of 1.41 compared with the simulated OR of 0.45 (Table 5 ). As expected, the frequentist and noninformative Bayesian analyses showed ORs close to the true values. Informative Bayesian analyses, using for example, a sample size of 1,000 subjects, showed ORs in men ranging from 1.07 (skeptical prior) to 1.49 (optimistic prior). Similarly, the OR in women ranged from 2.03 (skeptical prior) to 1.05 (optimistic prior). In the same scenario, interaction effects based on informative priors ranged from 0.53 (skeptical prior) to 1.26 (optimistic prior). In these cases, power and type 1 error rates were both affected, with observed power as low as 0% (ie, interaction effect and female subgroup) and type 1 error rates as high as 100% (male subgroup; Table 5 ).
Discussion
In this proof of principle study, we showed that, in most of the explored scenarios, incorporating prior knowledge using a Bayesian analysis of a postlaunch RCT increases the power to detect interaction effects at the cost of an increase in bias. For example, in one of our simulations Abbreviations: RCT, randomized clinical trial; OR, odds ratio. a Note all scenarios were repeated using a RCT including 15% women (Appendix). Changes from the default scenario are italicized.
( Table 3 , N 5 5,000), the power of the interaction test was 62% using a frequentist approach compared with a power of 83% (93% using a Bayesian approach). Bias increased from À0.01 for the frequentist estimate to at most 0.33 for the Bayesian estimate. Alternatively phrased, to gain a similar power (62%) as the frequentist analysis, the Bayesian method required 22%d48% fewer patients (ie, 3,914; 2,586 subjects instead of 5,000 subjects). This increase in power (or decrease in sample size) is clearly relevant for the detection of treatment effect modification Abbreviations: RCT, randomized clinical trial; OR, odds ratio; SE, standard error. a Women contributed 50% to the overall sample size N. In all simulations, Bayesian RCT analysis is compared with a frequentist analysis ignoring prior information. Subgroup-specific and interaction effect results are evaluated using the treatment OR, with the frequentist estimator reflecting the data likelihood and the Bayesian estimators the mean of the posterior distribution. Results were further evaluated using standard errors or from a Bayesian perspective standard deviations (SD), the percentage of times an OR of 1 was excluded by the 95% confidence or credibility interval (% reject). Depending on the true OR, the % reject should be interpreted as power or type 1 error rate. The noninformative prior is based on a normal distribution with a mean hyperparameter of 0 and variance of 10 6 ; the equivalent prior is based on a normal distribution with the reported ln OR x i and variance hyperparameter t 2 i equal to the simulated data; the skeptical prior uses the same mean and variance hyperparameters only now multiplying the variance by 4; the optimistic prior again uses the same point estimates from nonrandomized data but now uses a variance of 0.027 for each subgroup. All simulation results are based on 10,000 repetitions. and adverse events, for which RCTs are notoriously underpowered.
Previous research on Bayesian RCT analyses [7, 16, 17] , some also focusing on effect modification [18e20], shows that noninformative priors could be used to guard against multiplicity. Use of informative priors has also been considered. Most focus on using expert opinion to elicitate prior distributions [21e24] . These studies show that, if done carefully, Abbreviations: RCT, randomized clinical trial; OR, odds ratio; SE, standard error. a Women contributed 50% to the overall sample size N. In all simulations, Bayesian RCT analysis is compared with a frequentist analysis ignoring prior information. Subgroup-specific and interaction effect results are evaluated using the treatment OR, with the frequentist estimator reflecting the data likelihood and the Bayesian estimators the mean of the posterior distribution. Results were further evaluated using standard errors or from a Bayesian perspective standard deviations (SD), the percentage of times an OR of 1 was excluded by the 95% confidence or credibility interval (% reject). Depending on the true OR, the % reject should be interpreted as power or type 1 error rate. The noninformative prior is based on a normal distribution with a mean hyperparameter of 0 and variance of 10 6 ; the equivalent prior is based on a normal distribution with the reported ln OR x i and variance hyperparameter t 2 i equal to the simulated data; the skeptical prior uses the same mean and variance hyperparameters only now multiplying the variance by 4; the optimistic prior again uses the same point estimates from nonrandomized data but now uses a variance of 0.027 for each subgroup. All simulation results are based on 10,000 repetitions.
meaningful results can be expected using expert opinione based prior distributions. Our manuscript contributes to these articles by focusing on prior distributions based on nonrandomized study results. To some researchers, using informative priors based on nonrandomized studies may seem more objective than using expert opinion. However, there is still subjectivity about which nonrandomized studies to include and which variance hyperparameter to choose. Abbreviations: RCT, randomized clinical trial; OR, odds ratio; SE, standard error. a Women contributed 50% to the overall sample size N. In all simulations, Bayesian RCT analysis is compared with a frequentist analysis ignoring prior information. Subgroup-specific and interaction effect results are evaluated using the treatment OR, with the frequentist estimator reflecting the data likelihood and the Bayesian estimators the mean of the posterior distribution. Results were further evaluated using standard errors or from a Bayesian perspective standard deviations (SD), the percentage of times an OR of 1 was excluded by the 95% confidence or credibility interval (% reject). Depending on the true OR, the % reject should be interpreted as power or type 1 error rate. The noninformative prior is based on a normal distribution with a mean hyperparameter of 0 and variance of 10 6 ; the equivalent prior is based on a normal distribution with the reported ln OR x i and variance hyperparameter t 2 i equal to the simulated data; the skeptical prior uses the same mean and variance hyperparameters only now multiplying the variance by 4; the optimistic prior again uses the same point estimates from nonrandomized data but now uses a variance of 0.027 for each subgroup. All simulation results are based on 10,000 repetitions.
We feel that the following points deserve discussion. First, the Bayesian analyses of RCTs were evaluated based on power and type 1 error. These metrics are usually exclusive to frequentist analyses after the NeymanePearson perspective. However, given that, at completion of a postlaunch RCT, decisions may have to be made on continued market access, for example, by drug regulatory agencies such as EMA or FDA, we feel that these metrics are relevant [25, 26] . Second, it might seem inappropriate to combine information from nonrandomized studies with RCT data because the results of RCTs are typically of higher quality. However, it seems equally inappropriate to exclude information simply because treatment was not randomly allocated, especially in studies of adverse events [27e29]. We feel that it is time for a more inclusive view on interventional research formally incorporating information from multiple sources.
To reach such an inclusive view, we wish to note the following. We showed that Bayesian RCT analyses, using informative priors, can increase power at the potential cost of an increase in bias. This trade-off between power and bias might be acceptable for interaction effects because the power of interaction tests is notoriously limited [1, 13, 30] . Also note that including prior knowledge in an RCT analysis does not necessarily always increase bias. For example, because the prior for the male subgroup-specific effect was very compatible with the RCT estimate (eg , Table 3 ), the posterior effect estimate was practically unbiased. Because of the inclusion of prior information, however, the posterior estimate was more precise than the frequentist or noninformative estimates. When designing an RCT, we suggest that if one is confident about the direction of an effect, an informative prior based on nonrandomized studies might be used. This will result in a decrease in the number of patients who need to be randomized to a potentially inferior treatment, a reduction in costs, and in posterior effect estimates reflecting all available (nonconflicting) evidence. In designing such a Bayesian postlaunch RCT, similar to the more familiar sample size calculation, we suggest researchers to use simulations to gain insight in how the prior knowledge may influence the posterior distribution.
If, after data collection, the RCT data unexpectedly contradict the prior distribution, the use of informative priors might seem inappropriate. Indeed, our simulations showed a large increase in type 1 error rate and almost meaningless power. However, instead of simply ignoring the nonrandomized study results, as is current practice, we feel that in such settings, it is essential to discuss and explore why RCTs and prior information differed. To be meaningful, this discussion should go beyond a statement on the hierarchy of study design and the known shortcomings of nonrandomized studies (most notably the potential for confounding). Furthermore, the possibility that the data and the prior information disagree might seem a shortcoming of Bayesian RCT analyses. We feel, however, that when the data contradict the prior information, further research is needed. Because Bayesian methods will emphasize such contradictory findings and fuel the need for additional research, we see this as a virtue rather than a shortcoming.
Specifically, for the analysis of adverse events, it is important to take into account the type of adverse event (A or B) [31, 32] . Type A adverse events result from the primary mechanism of action of the intervention. Therefore, confounding by indication seems more likely, and this should be reflected in the prior distribution. However, for type B adverse events, the underlying mechanism is often unknown, thus decreasing the potential for confounding that should also be reflected in the prior belief. Initiating an RCT to study adverse events (notably type B) seems unlikely (due to the huge sample size typically required). However, pooling results from RCTs (initiated to study an intended effect) and nonrandomized studies on adverse event (using Bayesian methods) appears a viable and highly advisable alternative.
In conclusion, Bayesian analysis of postlaunch RCTs using informative priors will likely bias estimates of treatment effects. However, when the prior information and the expected RCT results are in the same direction, the decrease in variance can lead to relatively higher power of the Bayesian analysis with an acceptable degree of bias. This trade-off between power and bias might be acceptable for interaction effects because most RCTs only have limited power to detect these effects.
